We are analyzing https://link.springer.com/article/10.1007/s10555-011-9303-2.

Title:
Prostaglandin E2 EP receptors as therapeutic targets in breast cancer | Cancer and Metastasis Reviews
Description:
Prostaglandins are lipid compounds that mediate many physiological effects. Prostaglandin E2 (PGE2) is the most abundant prostanoid in the human body, and synthesis of PGE2 is driven by cyclooxygenase enzymes including COX-2. Both elevated expression of COX-2 and increased PGE2 levels have been associated with many cancers including breast cancer. PGE2 exerts its effect by binding to the E series of prostaglandin receptors (EP) which are G protein-coupled receptors. Four EP receptor subtypes exist, EP1–4, and each is coupled to different intracellular signaling pathways. As downstream effectors of the COX-2 pathway, EP receptors have been shown to play a role in breast and other malignancies and in cancer metastasis. The role of each EP receptor in malignant behavior is complex and involves the interplay of EP receptor signaling on the tumor cell, on stromal cells, and on host immune effector cells. While preclinical and epidemiological data support the use of nonsteroidal anti-inflammatory drugs and selective COX-2 inhibitors (COXibs) for the prevention and treatment of malignancy, toxicities due to COXibs as well as less than promising results from clinical trials have laboratories seeking alternative targets. As knowledge concerning the role of EP receptors in cancer grows, so does the potential for exploiting EP receptors as therapeutic targets for the treatment or prevention of cancer and cancer metastasis.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure if the website is profiting.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

google, scholar, cas, pubmed, cancer, prostaglandin, journal, breast, receptor, research, receptors, human, expression, cells, signaling, cell, cyclooxygenase, metastasis, fulton, cox, pharmacology, immunology, molecular, pge, risk, article, biological, tumor, clinical, sugimoto, national, activation, prostaglandins, prostanoid, role, nonsteroidal, antiinflammatory, drugs, chemistry, subtype, prevention, kundu, activity, nature, aspirin, european, pathway, treatment, access, medicine,

Topics {✒️}

g-protein-coupled receptors signalling granulocyte-macrophage colony-stimulating factor ep4-βarrestin1-c-src signalsome prostaglandin-e-receptor ep3 subtype g-protein-coupled receptors accessory-cell-derived products month download article/chapter agonist-induced internalization patterns t-cell line jurkat lipid raft-dependent manner gq/plc/ca2+ pathway hypoxia-inducible factor-1 alpha cutaneous uvb-induced inflammation pertussis toxin-sensitive inhibitory steroidal anti-inflammatory drugs t-cell cytokine secretion ep1/ep3-dependent mechanism nonsteroidal anti-inflammatory drugs fas-mediated cellular cytotoxicity c-terminal tail coupling castration-resistant prostate cancer gbetagamma subunit-independent manner c3h/hen peritoneal macrophages ep2/ep4 receptor signaling nonsteroidal anti-inflammatory drug protein-coupled receptors breast cancer-related proteins prostaglandin e2 promotes hepatocellular carcinoma cells prostaglandin e2 receptors cyclooxygenase-2-dependent signaling natural killer cells t-cell p59 prostanoid receptors ep3 cyclooxygenase-2 inhibits metastasis prostaglandin e2 receptor th17 cell expansion high metastatic potential ep3 receptor signaling tissue-specific distributions privacy choices/manage cookies receptor ep4 pathway distinct receptor subtypes full article pdf human ep3 receptor receptor ep3 isoforms cyclooxygenase/prostaglandin signaling lymphangiogenic factor vegf prostaglandin e2 modulates receptor ep1 subtype

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Prostaglandin E2 EP receptors as therapeutic targets in breast cancer
         description:Prostaglandins are lipid compounds that mediate many physiological effects. Prostaglandin E2 (PGE2) is the most abundant prostanoid in the human body, and synthesis of PGE2 is driven by cyclooxygenase enzymes including COX-2. Both elevated expression of COX-2 and increased PGE2 levels have been associated with many cancers including breast cancer. PGE2 exerts its effect by binding to the E series of prostaglandin receptors (EP) which are G protein-coupled receptors. Four EP receptor subtypes exist, EP1–4, and each is coupled to different intracellular signaling pathways. As downstream effectors of the COX-2 pathway, EP receptors have been shown to play a role in breast and other malignancies and in cancer metastasis. The role of each EP receptor in malignant behavior is complex and involves the interplay of EP receptor signaling on the tumor cell, on stromal cells, and on host immune effector cells. While preclinical and epidemiological data support the use of nonsteroidal anti-inflammatory drugs and selective COX-2 inhibitors (COXibs) for the prevention and treatment of malignancy, toxicities due to COXibs as well as less than promising results from clinical trials have laboratories seeking alternative targets. As knowledge concerning the role of EP receptors in cancer grows, so does the potential for exploiting EP receptors as therapeutic targets for the treatment or prevention of cancer and cancer metastasis.
         datePublished:2011-10-15T00:00:00Z
         dateModified:2011-10-15T00:00:00Z
         pageStart:449
         pageEnd:463
         sameAs:https://doi.org/10.1007/s10555-011-9303-2
         keywords:
            Prostaglandin
            Cyclooxygenase
            Cancer
            EP receptors
            Cancer Research
            Oncology
            Biomedicine
            general
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10555-011-9303-2/MediaObjects/10555_2011_9303_Fig1_HTML.gif
         isPartOf:
            name:Cancer and Metastasis Reviews
            issn:
               1573-7233
               0167-7659
            volumeNumber:30
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Jocelyn Reader
               affiliation:
                     name:University of Maryland Marlene and Stewart Greenebaum Cancer Center
                     address:
                        name:University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, USA
                        type:PostalAddress
                     type:Organization
                     name:University of Maryland School of Medicine
                     address:
                        name:Department of Pathology, University of Maryland School of Medicine, Baltimore, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Dawn Holt
               affiliation:
                     name:University of Maryland School of Medicine
                     address:
                        name:Department of Pathology, University of Maryland School of Medicine, Baltimore, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Amy Fulton
               affiliation:
                     name:University of Maryland Marlene and Stewart Greenebaum Cancer Center
                     address:
                        name:University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, USA
                        type:PostalAddress
                     type:Organization
                     name:University of Maryland School of Medicine
                     address:
                        name:Department of Pathology, University of Maryland School of Medicine, Baltimore, USA
                        type:PostalAddress
                     type:Organization
                     name:Baltimore Veterans Administration
                     address:
                        name:Baltimore Veterans Administration, Baltimore, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Prostaglandin E2 EP receptors as therapeutic targets in breast cancer
      description:Prostaglandins are lipid compounds that mediate many physiological effects. Prostaglandin E2 (PGE2) is the most abundant prostanoid in the human body, and synthesis of PGE2 is driven by cyclooxygenase enzymes including COX-2. Both elevated expression of COX-2 and increased PGE2 levels have been associated with many cancers including breast cancer. PGE2 exerts its effect by binding to the E series of prostaglandin receptors (EP) which are G protein-coupled receptors. Four EP receptor subtypes exist, EP1–4, and each is coupled to different intracellular signaling pathways. As downstream effectors of the COX-2 pathway, EP receptors have been shown to play a role in breast and other malignancies and in cancer metastasis. The role of each EP receptor in malignant behavior is complex and involves the interplay of EP receptor signaling on the tumor cell, on stromal cells, and on host immune effector cells. While preclinical and epidemiological data support the use of nonsteroidal anti-inflammatory drugs and selective COX-2 inhibitors (COXibs) for the prevention and treatment of malignancy, toxicities due to COXibs as well as less than promising results from clinical trials have laboratories seeking alternative targets. As knowledge concerning the role of EP receptors in cancer grows, so does the potential for exploiting EP receptors as therapeutic targets for the treatment or prevention of cancer and cancer metastasis.
      datePublished:2011-10-15T00:00:00Z
      dateModified:2011-10-15T00:00:00Z
      pageStart:449
      pageEnd:463
      sameAs:https://doi.org/10.1007/s10555-011-9303-2
      keywords:
         Prostaglandin
         Cyclooxygenase
         Cancer
         EP receptors
         Cancer Research
         Oncology
         Biomedicine
         general
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10555-011-9303-2/MediaObjects/10555_2011_9303_Fig1_HTML.gif
      isPartOf:
         name:Cancer and Metastasis Reviews
         issn:
            1573-7233
            0167-7659
         volumeNumber:30
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Jocelyn Reader
            affiliation:
                  name:University of Maryland Marlene and Stewart Greenebaum Cancer Center
                  address:
                     name:University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, USA
                     type:PostalAddress
                  type:Organization
                  name:University of Maryland School of Medicine
                  address:
                     name:Department of Pathology, University of Maryland School of Medicine, Baltimore, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Dawn Holt
            affiliation:
                  name:University of Maryland School of Medicine
                  address:
                     name:Department of Pathology, University of Maryland School of Medicine, Baltimore, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Amy Fulton
            affiliation:
                  name:University of Maryland Marlene and Stewart Greenebaum Cancer Center
                  address:
                     name:University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, USA
                     type:PostalAddress
                  type:Organization
                  name:University of Maryland School of Medicine
                  address:
                     name:Department of Pathology, University of Maryland School of Medicine, Baltimore, USA
                     type:PostalAddress
                  type:Organization
                  name:Baltimore Veterans Administration
                  address:
                     name:Baltimore Veterans Administration, Baltimore, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer and Metastasis Reviews
      issn:
         1573-7233
         0167-7659
      volumeNumber:30
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Maryland Marlene and Stewart Greenebaum Cancer Center
      address:
         name:University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, USA
         type:PostalAddress
      name:University of Maryland School of Medicine
      address:
         name:Department of Pathology, University of Maryland School of Medicine, Baltimore, USA
         type:PostalAddress
      name:University of Maryland School of Medicine
      address:
         name:Department of Pathology, University of Maryland School of Medicine, Baltimore, USA
         type:PostalAddress
      name:University of Maryland Marlene and Stewart Greenebaum Cancer Center
      address:
         name:University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, USA
         type:PostalAddress
      name:University of Maryland School of Medicine
      address:
         name:Department of Pathology, University of Maryland School of Medicine, Baltimore, USA
         type:PostalAddress
      name:Baltimore Veterans Administration
      address:
         name:Baltimore Veterans Administration, Baltimore, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Jocelyn Reader
      affiliation:
            name:University of Maryland Marlene and Stewart Greenebaum Cancer Center
            address:
               name:University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, USA
               type:PostalAddress
            type:Organization
            name:University of Maryland School of Medicine
            address:
               name:Department of Pathology, University of Maryland School of Medicine, Baltimore, USA
               type:PostalAddress
            type:Organization
      name:Dawn Holt
      affiliation:
            name:University of Maryland School of Medicine
            address:
               name:Department of Pathology, University of Maryland School of Medicine, Baltimore, USA
               type:PostalAddress
            type:Organization
      name:Amy Fulton
      affiliation:
            name:University of Maryland Marlene and Stewart Greenebaum Cancer Center
            address:
               name:University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, USA
               type:PostalAddress
            type:Organization
            name:University of Maryland School of Medicine
            address:
               name:Department of Pathology, University of Maryland School of Medicine, Baltimore, USA
               type:PostalAddress
            type:Organization
            name:Baltimore Veterans Administration
            address:
               name:Baltimore Veterans Administration, Baltimore, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, USA
      name:Department of Pathology, University of Maryland School of Medicine, Baltimore, USA
      name:Department of Pathology, University of Maryland School of Medicine, Baltimore, USA
      name:University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, USA
      name:Department of Pathology, University of Maryland School of Medicine, Baltimore, USA
      name:Baltimore Veterans Administration, Baltimore, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(317)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.78s.

LINK . SPRINGER . COM {}